Stock ATOS ATOSSA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Atossa Therapeutics, Inc.

Equities

ATOS

US04962H5063

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
1.49 USD +4.93% Intraday chart for Atossa Therapeutics, Inc. -3.25% +69.32%
Apr. 15 Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer CI
Apr. 09 Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib in Women with ER+/HER2- Breast Cancer
AQ
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
AQ
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer
CI
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
AQ
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
AQ
Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
CI
North American Morning Briefing : Stocks Seen -2-
DJ
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
AQ
Atossa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved 'Expanded Access' Program for a U.S. Breast Cancer Patient
AQ
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
AQ
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for A U.S. Breast Cancer Patient
CI
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
AQ
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
AQ
Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors
CI
Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting
AQ
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
AQ
Atossa Therapeutics, Inc. Announces First Patient Dosed with Selective Estrogen Receptor Modulator in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
CI
Atossa Therapeutics Rises After HC Wainwright Starts Coverage with Buy Rating
MT
HC Wainwright Initiates Atossa Therapeutics With Buy Rating, Price Target is $4
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATOS Stock
  4. News Atossa Therapeutics, Inc.